Essex Bio-Technology
Hong Kong SARessexbio.com
Overview
Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures, and commercializes genetically engineered therapeutic rb-bFGF (FGF-2). Its products are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. The company is publicly listed on the Hong Kong Stock Exchange and, through a subsidiary named Essex Bio-Investment, also makes strategic investments in other companies. The company's products are sold in approximately 14,100 hospitals in China.
Portfolio Companies
5
Website
essexbio.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| X-ZELL | Oct 2020 | Seed | Co-investor |
| KroniKare | Oct 2020 | Series A | Co-investor |
| Antikor Biopharma | Jul 2019 | VC Round | Lead |
| YesDok | Jun 2019 | Convertible Debt | Co-investor |
| Mitotech | Jul 2018 | Strategic | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
